| pubmed-article:9247575 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9247575 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:9247575 | lifeskim:mentions | umls-concept:C1332717 | lld:lifeskim |
| pubmed-article:9247575 | lifeskim:mentions | umls-concept:C1706438 | lld:lifeskim |
| pubmed-article:9247575 | lifeskim:mentions | umls-concept:C0085358 | lld:lifeskim |
| pubmed-article:9247575 | lifeskim:mentions | umls-concept:C0018129 | lld:lifeskim |
| pubmed-article:9247575 | lifeskim:mentions | umls-concept:C0079189 | lld:lifeskim |
| pubmed-article:9247575 | lifeskim:mentions | umls-concept:C1413244 | lld:lifeskim |
| pubmed-article:9247575 | lifeskim:mentions | umls-concept:C2698600 | lld:lifeskim |
| pubmed-article:9247575 | lifeskim:mentions | umls-concept:C0301625 | lld:lifeskim |
| pubmed-article:9247575 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:9247575 | pubmed:dateCreated | 1997-8-25 | lld:pubmed |
| pubmed-article:9247575 | pubmed:abstractText | A major histocompatibility complex (MHC) class I-specific T cell receptor (TCR)-transgenic mouse was used to study classical-type transplantation tolerance in the adult. Engraftment of MHC class I-incompatible bone marrow and tolerance to donor-type skin grafts were obtained using dimethylmyeleran (DMM) as a myeloablative agent and a non-depleting anti-CD8 monoclonal antibody (mAb) as the sole immunosuppressant. Surprisingly, bone marrow engraftment was facilitated by host CD4+ T cells, a subset normally considered unable to reject class I MHC-incompatible grafts. A combination of mAb to interleukins (IL)-4 and -10 antagonized the "permissive" effects of host CD4+ T cells, indicating a possible role for Th2-type immunoregulation that can act on CD8+ T cells in this form of transplantation tolerance. The fate of graft-reactive T cells was monitored using anti-clonotypic antibodies. It was observed that bone marrow engraftment then led to peripheral deletion of mAb-blockaded, clonotype+ CD8+ T cells. | lld:pubmed |
| pubmed-article:9247575 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9247575 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9247575 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9247575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9247575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9247575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9247575 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9247575 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:9247575 | pubmed:issn | 0014-2980 | lld:pubmed |
| pubmed-article:9247575 | pubmed:author | pubmed-author:WaldmannHH | lld:pubmed |
| pubmed-article:9247575 | pubmed:author | pubmed-author:ArnoldBB | lld:pubmed |
| pubmed-article:9247575 | pubmed:author | pubmed-author:ScullyRR | lld:pubmed |
| pubmed-article:9247575 | pubmed:author | pubmed-author:CobboldS PSP | lld:pubmed |
| pubmed-article:9247575 | pubmed:author | pubmed-author:MellorA LAL | lld:pubmed |
| pubmed-article:9247575 | pubmed:author | pubmed-author:WissingMM | lld:pubmed |
| pubmed-article:9247575 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9247575 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:9247575 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9247575 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9247575 | pubmed:pagination | 1663-70 | lld:pubmed |
| pubmed-article:9247575 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:meshHeading | pubmed-meshheading:9247575-... | lld:pubmed |
| pubmed-article:9247575 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9247575 | pubmed:articleTitle | A role for Th2 cytokines in the suppression of CD8+ T cell-mediated graft rejection. | lld:pubmed |
| pubmed-article:9247575 | pubmed:affiliation | Department of Pathology, University of Cambridge, GB. | lld:pubmed |
| pubmed-article:9247575 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9247575 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9247575 | lld:pubmed |
